2 Equal-Weight ETFs To Boost Returns This Earnings Season
Tezcan Gecgil/Investing.com | Jul 21, 2022 15:50
- Equal-weight ETFs invest equally between all holdings
- Inherently value-based
- Can mitigate risk as diversifies based on value
- Current Price: $82.76
- 52-week range: $75.69 - $99.00
- Dividend yield: 1.20%
- Expense ratio: 0.40% per year
- Current Price: $84.52
- 52-week range: $61.78 - $136.61
- Expense ratio: 0.35% per year
- Novavax (NASDAQ:NVAX), which has been in the news for its COVID-19 vaccine.
- Precision genetic medicines developer Beam Therapeutics (NASDAQ:BEAM).
- Clinical-stage biopharma group Fate Therapeutics (NASDAQ:FATE).
- Global Blood Therapeutics Inc (NASDAQ:GBT), which has been focusing on sickle cell disease (SCD).
Wall Street is enjoying a positive week, thanks to robust reports in some of the oversold growth names. However, as the earnings season progresses, we will likely see increased volatility.
Many analysts agree that equal-weight (EQW) exchange-traded funds (ETFs) can help mitigate the risk of being over-concentrated in a handful of stocks by offering a diversified portfolio based on value.
An index or a fund with such holdings must constantly rebalance the portfolio as share prices change--thus selling high and buying low. This feature sets it apart from the traditional market capitalization (MCAP) method, where the market capitalization of each holding becomes important.
For example, the S&P 500 Equal Weighted Index, which weights members of the S&P 500 equally, has declined 14.4% since January, while the S&P 500 lost 16.9%.
Research by Solactive, which designs financial indices, :
“The better returns of the EQW method are also partly explained by what we call a “rebalancing effect” – i.e., bringing stocks back to equal weight, essentially buying low and selling high – something not present in MCAP weighted portfolios….”
With that information, here are two equal-weighted ETFs to consider during this earnings season.
h2 1. Invesco S&P MidCap 400 Equal Weight ETF /h2
Get The App
Mid-cap companies are those that typically have market capitalizations (caps) of between $2 billion and $10 billion. Most financial planners suggest long-term investors include mid-cap stocks or funds that invest in them.
Research :
“Not only have mid-cap stocks generated higher absolute returns over a longer time frame, but they have also provided these returns with less associated risk.”
Mid-caps typically grow their earnings fast and also frequently become takeover targets.
The first fund we will discuss is the Invesco S&P MidCap 400 Equal Weight ETF (NYSE:EWMC). It provides to US mid-cap names. The fund started trading in December 2010, and net assets stand at 109.8 million.
EWMC, which tracks the S&P MidCap 400 Equal Weight Index, has 402 holdings. Both the index and fund are rebalanced quarterly. With regards to sector breakdown, we see Industrials (16.97%), Consumer Discretionary (15.72%), Financials (15.29%), Information Technology (12.58%), Health Care (10.80), and others.
About 3% of the portfolio is in the top 10 stocks. Among them are Arrowhead Pharmaceuticals (NASDAQ:ARWR), retailer Ollies Bargain Outlet Holdings (NASDAQ:OLLI), restaurant group Wingstop (NASDAQ:WING), and Performance Food Group (NYSE:PFGC), which distributes food products.
EWMC hit a record high in mid-November 2021. But since then, shares in the ETF have come under pressure, and the fund is down around 14.2% YTD. Forward price-to-earnings (P/E) and price-to-book (P/B) ratios stand at 12.35x and 2.20x, respectively. Investors interested in mid-caps' growth within an EQW wrapper should research the fund further.
h2 2. SPDR S&P Biotech ETF /h2The second ETF we will be discussing is the SPDR S&P Biotech ETF (NYSE:XBI) which invests primarily in the biotechnology segment of the S&P index. The fund started trading in January 2006.
XBI currently has 135 holdings where the leading 10 comprise about 15% of net assets of $7.76 billion:
Most biotechnology names have come under pressure in the past year. As a result, the fund has lost 24.5% since January and 33.9% over the past year. Trailing P/E and P/B ratios are 11.65x and 3.58x, respectively. We like the diversity of XBI and believe long-term biotech investors could consider buying it around these levels.
Disclaimer: On the date of publication, Tezcan Gecgil, Ph.D., did not have any positions in the securities mentioned in this article.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.